^
Association details:
| Biomarker: | VEGFA expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment
Excerpt:
...The expression of VEGF, VEGFR1, and VEGFR2 by serous epithelial ovarian carcinoma is the primary end point, and the secondary end point is the response of serous ovarian carcinoma to the therapy with bevacizumab (Avastin), paclitaxel and carboplatin....
Trial ID:
Source:
Title:
Bevacizumab may differentially improve prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an anti-angiogenic VEGF-A splice variant
Published date:
08/24/2022
Excerpt:
In patients with low VEGF-A165b expression, the addition of bevacizumab to standard platinum-based chemotherapy significantly improved progression-free (HR: 0.727, 95%CI=0.538 - 0.984; p=0.039) and overall survival (HR: 0.662, 95%CI=0.458 - 0.958; p=0.029). Multivariate analysis showed that the addition of bevacizumab in low VEGF-A165b expressing patients conferred significant improvements in progression-free survival (HR: 0.610, 95%CI=0.446 - 0.834; p=0.002) and overall survival (HR: 0.527, 95%CI=0.359 - 0.775; p=0.001), independently from established risk factors.
Secondary therapy:
Chemotherapy
DOI:
10.1158/1078-0432.CCR-22-1326
